 | Up a level |
Jump to: Journal Article
Number of items: 1.
Journal Article
El-Khoueiry, Anthony B., Kim, Richard D., Harris, William Proctor, Sung, Max W., Waldschmidt, Dirk, Cabrera, Roniel, Garosi, Vittorio Luigi, Zebger-Gong, Hong, Brennan, Barbara J., Wang, Ying A., Mueller, Udo, Ishida, Tatiane Cristine and Galle, Peter R. (2021). Updated results of a phase 1b study of regorafenib (REG) 80 mg/day or 120 mg/day plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC). J. Clin. Oncol., 39 (15). PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1527-7755